|
1) Sinha S, Newsom-Davis J, Mills K, et al. Autoimmune aetiology for acquired neuromyo-tonia (Isaacsʼ syndrome). Lancet. 1991; 338: 75-7
|
|
|
|
2) Arimura K, Sonoda Y, Watanabe O, et al. Isaccsʼ syndrome as a potassium channelopathy of the nerve. Muscle Nerve. 2002; Suppl 11: S55-8
|
|
|
|
|
|
3) Sonoda Y, Arimura K, Kurono A, et al. Serum of Isaacsʼ syndrome suppresses potassium channels in PC-12 cell lines. Muscle Nerve. 1996; 19: 1439-46
|
|
|
|
|
|
4) Nagado T, Arimura K, Sonoda Y, et al. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain. 1999; 122: 2057-66
|
|
|
|
|
|
5) Tomimitsu H, Arimura K, Nagado T, et al. Mechanism of action of voltage-gated K＋ channel antibodies in acquired neuromyotonia. Ann Neurol. 2004; 56: 440-4
|
|
|
|
|
|
6) Liguori R, et al. Morvanʼs syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 2001; 124: 2417-26
|
|
|
|
|
|
7) Irani SR, Pettingill P, Kleopa KA, et al. Morvanʼs syndrome: clinical and serological obsevations in 29 cases. (under submitting)
|
|
|
|
|
|
8) Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001; 50: 73-8
|
|
|
|
|
|
9) Vincent A, Buckley C, Scgiet al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004; 127: 701-12
|
|
|
|
|
|
10) Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004; 62: 1177-82
|
|
|
|
|
|
11) Soeder BM, Gleissner U, Urbach H, et al. Causes, presentation and outcome of lesional adult onset mediotemporal lobe epilepsy. J Neurol Neurosurg Psychiatry. 2009; 80: 894-9
|
|
|
|
|
|
12) Iranzo A, Graus F, Clover L, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol. 2006; 59: 178-82
|
|
|
|
|
|
13) Tan M, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008; 70: 1883-90
|
|
|
|
|
|
14) Kleopa KA, Elman LB, Lang B, et al. Neuro-myotonia and limbic encephalitis sera target mature Shaker-type K＋ channels: subunit speci-ficity correlates with clinical manifestations. Brain. 2006; 129: 1570-84
|
|
|
|
|
|
15) Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010; 9: 776-85
|
|
|
|
|
|
16) Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactived 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvanʼs syndrome and acquired neuromyotonia. Brain. 2010; 133: 2734-48
|
|
|
|
|
|
17) Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol. 2002; 52: 364-7
|
|
|
|
|
|
18) Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet. 2002; 30: 335-41
|
|
|
|
|
|
19) Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet. 2002; 11: 1119-28
|
|
|
|
|
|
20) Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. PNAS. 2010; 107: 3799-804
|
|
|
|
|
|
21) Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science. 2006; 22: 1792-5
|
|
|
|
|
|
22) Poliak S, Gollan L, Martinez R, et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K＋ channels. Neuron. 1999; 24: 1037-47
|
|
|
|
|
|
23) Bel C, Oguievetskaia K, Pitaval C, et al. Axonal targeting of Caspr2 in hippocampal neurons via selective somatodendritic endocytosis. J Cell Sci. 2009; 122: 3403-13
|
|
|
|
|
|
24) Peñagarikano O, Abrahams BS, Herman EI, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011; 30: 235-46
|
|
|
|
|
|
25) Lancaster E, Hernandez EM, Dalmau J. En-cephalitis and antibodies to synaptic and neuro-nal cell surface proteins. Ann Neurol. 2011; 77: 179-89
|
|
|
|
|
|
26) Vincent A, Bien CG, Irani SR, et al. Auto-antibodies associated with diseases of the CNS: new developmetns and future challenges. Lancet Neurol. 2011; 10: 759-72
|
|
|
|
|
|
27) Lancaster E, Huijbers MG, Bar V, et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011; 69: 303-11
|
|
|
|
|